Analyst Samantha Semenkow from Citi reiterated a Buy rating on Biohaven Ltd. and keeping the price target at $28.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Samantha Semenkow’s rating is based on several factors, including the potential approval of Biohaven Ltd.’s drug, troriluzole, which is currently under review by the FDA. Despite some regulatory pressures and uncertainties, particularly following updates from other companies’ regulatory experiences, Semenkow remains optimistic about the approval prospects of troriluzole, viewing it as more likely than not to succeed.
Furthermore, the expected share price return of 62.8% suggests significant upside potential for investors. This optimistic outlook, combined with the high-risk nature of the investment, supports the Buy rating, as the potential rewards are deemed to outweigh the risks involved.
Semenkow covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, BioAge Labs, Inc., and Larimar Therapeutics. According to TipRanks, Semenkow has an average return of -4.8% and a 42.50% success rate on recommended stocks.